Talk:Schering-Plough
From Wikipedia, the free encyclopedia
 |
This article is within the scope of Companies WikiProject, a collaborative effort to improve Wikipedia's coverage of companies. If you would like to participate please visit the project page, where you can join the project and see a list of open tasks. | |
| ??? | This article has not yet received a rating on the assessment scale. | |
| ??? | This article has not yet received an importance rating assessment scale. | |
Contents |
[edit] German part of Schering
What happened to the German part of Schering (founded by Ernst Schering in 1851) during and after WWII? Were there any other parts elsewhere that were also severed from the German parent? Did Shering AG try to reposess the US division that was servered during the war? If not, why not? ... (I am sure that the answer to this specific questions raise follow-on questions...)
[edit] Controversy
Cindery (talk ยท contribs) added a long section on controversy. It was duplicated verbatim over here, so I've removed it for now (see history if necessary).
It is unclear how much of this is a direct quote from the NY Times article, a link for which is not provided. There is a possibility long direct quotes constitute a copyright violation, so I urge Cindery to rephrase the material in his/her own words. JFW | T@lk 21:22, 26 July 2006 (UTC)
[edit] Protection against seizures, founding fathers are rolling in grave
Did the USA pay compensation for the confiscation of Schering property during WWII? If not, should the WTO impose sanctions against USA to restore the rule of law? Private property stands above all values and is sancro-santc. 195.70.32.136 17:51, 2 September 2006 (UTC)
[edit] Error
I'm pretty sure that Schering-Plough worked with Merck to market Vytorin which is a combination of Zetia (a Schering-Plough product) and Zocor (a Merck & Co. product)
[edit] Citations for consideration
- 2008-04-09: Consider http://www.drugdiscoverynews.com/index.php?newsarticle=2062 ... reports announcement to cut $1.5 billion in expense outlays in the wake of clinical trial results of Vytorin. This would go to documenting the impact of the Vytorin problems on the company. --User:Ceyockey (talk to me) 02:50, 10 April 2008 (UTC)
